Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Sequencing immunotherapies in multiple myeloma

Samir Parekh • 2 Jun 2024
ASCO 2024
Multiple Myeloma Antibodies CAR-T

Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, discusses sequencing bispecific antibodies and CAR-Ts for multiple myeloma (MM). He emphasizes considering resistance mechanisms and switching target antigens if resistance occurs and suggests using autologous stem cell transplantation (autoSCT) as salvage therapy when treatments fail. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Samir Parekh

1:03
Looking forward to ASH 2021: key updates in multiple myeloma
Samir Parekh • 10 Nov 2021
2:42
COVID-19 prophylaxis: bolstering boosters
Samir Parekh • 10 Nov 2021
9:04
How does myeloma treatment choice impact COVID-19 vaccination response?
Samir Parekh • 10 Nov 2021
2:32
Refining the current staging system for multiple myeloma
Samir Parekh • 10 Nov 2021

Related Videos

5:30
Linvoseltamab versus teclistamab for TCE RRMM and the sequencing of bispecifics with CAR-Ts
Sundar Jagannath • 3 Jun 2024
2:21
Cilta-cel versus SoC in functionally high-risk myeloma with one prior therapy
Luciano Costa • 2 Jun 2024
1:08
The impact of extramedullary multiple myeloma on outcomes with ide-cel
Saurabh Zanwar • 3 Jun 2024
0:49
The movement of BCMA-directed therapies to earlier lines in myeloma treatment
Amrita Krishnan • 2 Jun 2024
The content of VJHemOnc is intended for healthcare professionals